MedPath

Agomab Therapeutics Secures $89 Million to Advance Fibrotic Disease Treatments

  • Agomab Therapeutics has raised $89 million in Series D funding to support clinical trials for its fibrotic disease treatments, including AGMB-129.
  • AGMB-129, an oral small molecule inhibitor of ALK5 (TGFβ1R), is currently in a Phase IIa trial (STENOVA) for fibrostenosing Crohn’s disease, with interim results expected in early 2025.
  • The funding will also support the development of AGMB-447, an inhaled treatment for idiopathic pulmonary fibrosis (IPF), and AGMB-101, a liver cirrhosis candidate.
  • Sanofi and Invus have joined as new investors, highlighting the growing interest and investment in immunology and fibrotic disease treatments.
Agomab Therapeutics has announced the successful completion of an $89 million Series D funding round, which will be used to advance the clinical development of its pipeline of fibrotic disease treatments. The financing will primarily support the Phase IIa STENOVA trial of AGMB-129, an oral small molecule inhibitor targeting ALK5 (TGFβ1R) for fibrostenosing Crohn’s disease (FSCD). Sanofi and Invus joined the round as new investors.

Advancing AGMB-129 for Fibrostenosing Crohn’s Disease

AGMB-129 is currently being evaluated in the Phase IIa STENOVA trial (NCT05843578), a 90-patient study. The company anticipates sharing interim results from this trial in early 2025. FSCD is characterized by intestinal strictures caused by inflammation and scarring, and there is currently no cure for the condition. Positive data from a Phase I trial (NCT04933565) of AGMB-129, reported in February 2023, demonstrated high local exposure in the ileum, with no drug-related safety signals or dose-limiting toxicities.

Expanding Pipeline: IPF and Liver Cirrhosis

In addition to AGMB-129, the funding will support the development of AGMB-447, an inhaled treatment for idiopathic pulmonary fibrosis (IPF), which is currently in a Phase I trial (NCT06181370). Agomab also plans to initiate clinical development of AGMB-101, a candidate for liver cirrhosis, which is in the final stages of IND-enabling studies.

Sanofi's Continued Investment in Immunology

Sanofi's investment in Agomab is part of a broader strategy to expand its presence in the immunology space. Recently, Sanofi has engaged in multiple deals, including partnerships with Recludix, Teva Pharmaceutical, and IGM Biosciences. In June 2024, Sanofi entered a $700 million strategic partnership with Belharra Therapeutics to develop small molecule therapies for immunological diseases.

Leadership Perspective

"We are thrilled to have Sanofi and Invus joining our investor syndicate," said Tim Knotnerus, CEO of Agomab. "Their investment as well as the continued support from our existing shareholders is another validation of the trailblazing work our team is conducting in the fields of fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis."
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

89bio's Pegozafermin Advances in Phase 3 Trials for MASH and Severe Hypertriglyceridemia

89bio completed enrollment in the Phase 3 ENTRUST trial for severe hypertriglyceridemia (SHTG), with topline data expected in the second half of 2025.

RhyGaze Secures $86 Million Series A Funding to Advance Novel Gene Therapy for Vision Restoration

RhyGaze, a biotech firm based in Basel and Philadelphia, has secured $86 million in Series A funding to advance its gene therapy for vision restoration.

TNF Pharmaceuticals Advances Isomyosamine for Sarcopenia and GLP-1-Induced Muscle Loss

TNF Pharmaceuticals' isomyosamine demonstrated safety in a 13-week study, supporting longer clinical trials for multiple indications.

uniQure Receives FDA Nod for Accelerated Approval Pathway for Huntington's Disease Gene Therapy

uniQure secured FDA agreement to pursue accelerated approval for its Huntington's disease gene therapy, potentially expediting treatment availability.

IPF Drug Development Heats Up with Novel Targets and Clinical Advances

Refoxy Pharma secured $9.58 million to advance its FOXO3-targeting IPF drug, RP-01, aiming to modulate tissue repair mechanisms.

89bio's Pegozafermin Advances Through Phase 3 Trials for MASH and SHTG

89bio is progressing pegozafermin, a FGF21 analog, through Phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).

SynOx Therapeutics Raises $92 Million and Doses First Patients in Phase 3 TGCT Trial

SynOx Therapeutics secured $92 million in Series B funding to advance the Phase 3 TANGENT trial of emactuzumab for Tenosynovial Giant Cell Tumour (TGCT).

Guselkumab Shows Promise as Subcutaneous Induction Therapy for Crohn's Disease

Phase III data indicates guselkumab (TREMFYA®) is the first IL-23 inhibitor to demonstrate effectiveness via subcutaneous induction and maintenance in Crohn's disease.

Gilgamesh Pharmaceuticals Receives $14 Million NIDA Grant for Cardiac-Safe Ibogaine Analog to Treat Opioid Use Disorder

Gilgamesh Pharmaceuticals secured a $14 million grant from the National Institute on Drug Abuse (NIDA) to advance GM-3009, a novel ibogaine analog, for opioid use disorder (OUD).

Synergia Medical Secures €9 Million in Series B Funding for Epilepsy Treatment Innovation

Synergia Medical, a preclinical medical device company, has successfully raised €9 million in Series B funding. This financial boost will support the company's preparation for First-In-Human clinical trials of its NAO.VNS device, aimed at treating drug-resistant epilepsy, and the submission of an Investigational Device Exemption to the FDA in 2023.

Reference News

[1]
Sanofi-backed Agomab raises $89m to advance fibrotic disease treatments
pharmaceutical-technology.com · Oct 25, 2024

Agomab Therapeutics raises $89m in Series D funding, with Sanofi and Invus joining as new investors, to advance clinical...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy